The pancreas is a part of the human-body that is responsible for production of multiple hormones such as insulin
and glucagon, along with a few digestive enzymes to allow proper digestion of food items. Insulin allows body
cells to acquire glucose from the blood providing essential energy for their functioning, at the same time
lowering blood glucose levels. While, glucagon secreted by pancreases is responsible for releasing glucose that
is stored in the liver, raising overall blood glucose levels.
Type 1 diabetes commonly arises due to lower or almost negligible production of insulin that is needed to
regulate blood glucose level in the body. While, in type 2 diabetes production insulin or already present insulin
is resisted by body itself, causing adverse effects. The artificial pancreas device system is responsible for closely
monitoring the glucose level by mimicking functionality of a healthy pancreas. The common type of the artificial
pancreas device system utilized by number of diabetes patients these days are a constant glucose monitoring
(CGM) devices and an insulin infusion pump.
Browse Full Research Report @
https://www.millioninsights.com/industry-reports/artificial-pancreas-device-system-apds-market
Special types of devices are used such as a blood glucose devices or glucose meters to regulate the constant
glucose monitoring (CGM) system. A computerized system is implemented in order to manage constant glucose
monitoring (CGM) and insulin infusion pump, providing consistent communication between the two devices. An
artificial pancreas device system is also termed as a closed-loop system or an automated insulin delivery system.
The artificial pancreas device systems manage glucose level in blood, while regulating or automatically changing
the production of insulin in blood to decrease high blood glucose levels such as hyperglycemia. The artificial
pancreas device system also monitors and regulate low blood sugar level as required.
The artificial pancreas device system market is divided by region as North America, Europe, Asia-Pacific, Latin
America and Africa. North America has shown major growth in recent years owing to the rise adoption of latest
technologies in healthcare sector and existence well-established healthcare infrastructure. Asia-Pacific region is
predicted to hold the major market share in the artificial pancreas device system industry with massive growth
in the forecast period. Countries such as India, China and Singapore are leading the Asia-Pacific market with the
changing food habits, genetic modification, and growing elderly population. The key players in the artificial
pancreas device system market are Bigfoot Biomedical Co., Johnson & Johnson Inc., Tandem Diabetes Care
Incorporations, Pancreum, Incorporations, TypeZero Technologies, and Beta Bionics, Inc.
Market Segment:
Artificial Pancreas Device System Device Type Outlook (Revenue, USD Million, 2013 - 2024)
• Threshold suspended device system